Quick search:
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Regorafenib/Nivolumab Shows Modest Activity in MMR Proficient Advanced Refractory CRC
2 Regorafenib/Nivolumab Combo to Be Studied in Phase III Trial of Patients With MSS mCRC
3 Nivolumab Plus Regorafenib Regimen Active in Gastrointestinal Cancers
4 Dr. Grothey on Combination Therapies with Regorafenib and TAS-102 in CRC
5 Novel Combinations Dominate Later-Line Metastatic CRC Treatment Landscape
6 Regorafenib Plus Nivolumab Limits Tumor Growth In Gastric and Colorectal Cancers
7 Regorafenib/Nivolumab Combo Elicits Responses in CRC and Gastric Cancer
8 Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer
9 Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020
10 Immunotherapy Options Growing for Metastatic Colorectal Cancer
11 The Expanding Continuum of Care in Metastatic Colorectal Cancer
12 Bayer, BMS, Ono Pharma enter into clinical collaboration for colorectal cancer
13 [Full text] Safety and efficacy of neoadjuvant therapy in gastric cancer | CMAR
14 Bristol-Myers Squibb 2019: More of everything – PharmaLive